VANFLYTA

Indicated For

FLT3-ITD positive AML, newly diagnosed

About This Medication

# VANFLYTA Patient Assistance Program Patient Guide: How to Get VANFLYTA (quizartinib) at Low or No Cost VANFLYTA (quizartinib) is a prescription medication used to treat adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD-positive, in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, and as a single agent for relapsed or refractory cases.[1] The **VANFLYTA Patient Assistance Program** from **Daiichi Sankyo** offers eligible patients free medication if they lack insurance coverage or their insurance does not cover VANFLYTA.[1][6] ## Who Qualifies for the Program? This program targets patients facing financial barriers to accessing VANFLYTA. Key eligibility groups include: - **Uninsured patients**: Those without any health insurance. - **Underinsured patients**: Individuals whose insurance (commercial, private, or government) does not cover VANFLYTA treatment. - **Medicare patients**: Eligible if unable to afford out-of-pocket costs.[6][8] Patients must reside in the US or Puerto Rico and demonstrate financial need, though specific income thresholds like Federal Poverty Level (FPL) percentages are not publicly detailed.[1][6][8] The program assesses eligibility case-by-case, focusing on those unable to identify alternative payment sources.[5] Daiichi Sankyo reserves the right to modify or end the program at any time.[6] ## About VANFLYTA (quizartinib) **VANFLYTA** is an oral kinase inhibitor targeting FLT3 mutations, common in about 30% of AML patients. It helps block cancer cell growth in FLT3-ITD-positive AML, improving survival rates when added to chemotherapy.[1] Administered daily, it's available through specialty pharmacies like Biologics or Onco360.[3][6] Common side effects include nausea, vomiting, and low blood counts—discuss risks with your doctor. Always follow prescribing information and REMS requirements for safe use.[1] ## Income Eligibility Breakdown Detailed income limits are not specified in program materials; eligibility hinges on financial hardship for uninsured/underinsured patients.[1][6] Contact Daiichi Sankyo AccessCentral4U for personalized assessment. Here's a general overview based on similar programs: | Household Size | Typical Threshold Example (e.g., 400-500% FPL)* | Notes | |---------------|------------------------------------------------|-------| | Individual | ~$60,000-$75,000 annually | Assessed individually; no fixed limits listed[8] | | Couple | ~$80,000-$100,000 annually | Varies by case[6] | | Family of 3 | ~$100,000-$125,000 annually | Financial need required[5] | | Family of 4 | ~$120,000-$150,000 annually | Medicare patients enrolled year-end[6] | *Examples for illustration; actual eligibility determined by program. Call (866) 437-4669 for details.[3][6] ## Insurance Requirements You qualify if: - You have **no insurance**. - Your **insurance denies coverage** for VANFLYTA (includes commercial, Medicare, or Medicaid).[1][6][8] The specialty pharmacy conducts a benefits investigation to confirm.[3] Medicare patients can enroll but coverage lasts through December 31 of the approval year.[6] This program does not apply to commercially insured patients using the VANFLYTA Copay Program.[7] ## Step-by-Step Application Process 1. **Consult your doctor**: Ensure VANFLYTA is prescribed and discuss REMS certification.[1][3] 2. **Get the Patient Enrollment Form**: Download from DSAccessCentral4U.com or request via phone.[3][10] 3. **Complete required documents**: - Patient Enrollment Form (includes consent and physician attestation).[10] - Valid prescription for VANFLYTA.[1] 4. **Fax to specialty pharmacy**: Use 1-833-471-9988 or the pharmacy's fax (Biologics: 1-800-850-4306; Onco360: 1-877-662-6633).[3][6] 5. **Call for support**: Contact Daiichi Sankyo AccessCentral4U at **(866) 437-4669** (Mon-Fri, 8AM-6PM ET, excluding holidays) for help.[1][3][4] 6. **Eligibility review**: Pharmacy assesses benefits, prior authorizations, and PAP eligibility.[3][10] Multiple application methods are available, including phone and fax.[3] ## Timeline and Delivery Processing time varies; expect benefits investigation within days, with QuickStart offering a free 14-day supply if delays exceed 5 business days.[1][3] Uninsured patients get 12 months coverage from approval; Medicare through year-end.[6] Medication ships directly to your home via specialty pharmacy upon approval.[1][3] Track status by calling the support line. ## Alternatives if Denied or Ineligible - **VANFLYTA QuickStart Program**: Free 14-day starter for coverage delays.[1][3] - **VANFLYTA Copay Program**: For commercial insurance to reduce out-of-pocket costs.[6][7] - **Partnership for Prescription Assistance (PPA)**: Daiichi Sankyo member; find other programs at pparx.org.[2] - **Daiichi Sankyo Open Care Program**: Broader free meds for underinsured.[5] - **State assistance or generic options**: No biosimilars available; consult doctor.[8] Reapply if circumstances change.[6] ## Important Disclaimer This guide provides general information based on available sources as of 2026 and is not medical or legal advice. Eligibility, terms, and availability can change; Daiichi Sankyo does not guarantee access.[1][6] Consult your healthcare provider and contact AccessCentral4U directly for your situation. Programs may end abruptly. Word count: 950.

Program information last verified: March 30, 2026